BridgeBio Oncology Therapeutics (BBOT) vs Bicycle Therapeutics (BCYC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Bicycle Therapeutics (BCYC) has outperformed BridgeBio Oncology Therapeutics (BBOT) over the past year, losing 53.4% versus a loss of 71.8%. BridgeBio Oncology Therapeutics is the larger company by market cap ($275.8 million vs $261.1 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BBOT | BCYC |
|---|---|---|
| Share price | $3.44 | $3.73 |
| Market cap | $275.80M | $261.07M |
| 1-day change | -1.71% | -1.58% |
| YTD return | -72.52% | -47.32% |
| 1-year return | -71.83% | -53.37% |
| 5-year return | — | -93.71% |
| EPS (TTM) | $-0.07 | $-2.73 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $14.87 | $9.16 |
| 52-week low | $3.36 | $3.33 |
| Distance from 52-week high | -76.87% | -59.28% |
| Analyst consensus | none | none |
| Avg. price target upside | +613.66% | +154.69% |
| Average volume | 471.17K | 389.74K |
| Shares outstanding | 80.17M | 50.55M |
| Employees | 88 | 288 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BCYC has outperformed BBOT by 18.5 percentage points over the past year.
About BridgeBio Oncology Therapeutics
BBOT stock →BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States. The company develops BBO-8520, an orally bioavailable small molecule direct inhibitor, which is in Phase I clinical trial for the treatment of patients with KRASG12C mutant non-small cell lung cancer; and BBO-11818, an orally bioavailable small molecule pan-KRAS inhibitor, which is in Phase I clinical trial for the treatment of patients with KRAS G12D and KRAS G12V cell-derived xenograft models.
Health Care · Biotechnology: Pharmaceutical Preparations · 88 employees
About Bicycle Therapeutics
BCYC stock →Bicycle Therapeutics plc, a clinical-stage pharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. The company's products pipeline include zelenectide pevedotin, a bicycle toxin conjugate (BTC), which is in phase II clinical trials for the treatment of high nectin-4 expressing tumors; nuzefatide pevedotin (EphA2), a BTC that is in phase I/II clinical trials to treat Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle tumor-targeted immune cell agonist molecule, which is in phase I/II targeting nectin-4 and agonizing CD137; and BT1702, a theranostic BRC molecule targeting MT1-MMP for which IND-enabling activities are ongoing.
Health Care · Biotechnology: Pharmaceutical Preparations · 288 employees
BBOT vs BCYC FAQ
Which is bigger, BridgeBio Oncology Therapeutics or Bicycle Therapeutics?
BridgeBio Oncology Therapeutics (BBOT) is larger, with a market capitalization of $275.80M compared with $261.07M for Bicycle Therapeutics (BCYC).
Which stock has performed better over the past year, BBOT or BCYC?
BCYC returned -53.37% over the past 12 months, compared with -71.83% for BBOT (price return, excluding dividends). Past performance does not predict future results.
Are BridgeBio Oncology Therapeutics and Bicycle Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.